370 related articles for article (PubMed ID: 16758243)
1. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.
Schüle C; Baghai TC; Eser D; Zwanzger P; Jordan M; Buechs R; Rupprecht R
Psychopharmacology (Berl); 2006 Jul; 186(4):601-11. PubMed ID: 16758243
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine.
Schüle C; Baghai T; Zwanzger P; Ella R; Eser D; Padberg F; Möller HJ; Rupprecht R
Psychopharmacology (Berl); 2003 Mar; 166(3):271-5. PubMed ID: 12552362
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action.
Horstmann S; Dose T; Lucae S; Kloiber S; Menke A; Hennings J; Spieler D; Uhr M; Holsboer F; Ising M
Psychoneuroendocrinology; 2009 Feb; 34(2):238-248. PubMed ID: 18926641
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrinological mechanisms of actions of antidepressant drugs.
Schüle C
J Neuroendocrinol; 2007 Mar; 19(3):213-26. PubMed ID: 17280595
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test.
Künzel HE; Binder EB; Nickel T; Ising M; Fuchs B; Majer M; Pfennig A; Ernst G; Kern N; Schmid DA; Uhr M; Holsboer F; Modell S
Neuropsychopharmacology; 2003 Dec; 28(12):2169-78. PubMed ID: 12931142
[TBL] [Abstract][Full Text] [Related]
6. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
Sher L; Oquendo MA; Burke AK; Cooper TB; Mann JJ
J Affect Disord; 2013 Dec; 151(3):1108-12. PubMed ID: 23866302
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of HPA axis hyperactivity and simultaneous clinical deterioration in a depressed patient treated with mirtazapine.
Schüle C; Baghai T; Zwanzger P; Rupprecht R
World J Biol Psychiatry; 2001 Apr; 2(2):103-5. PubMed ID: 12587193
[TBL] [Abstract][Full Text] [Related]
8. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
[TBL] [Abstract][Full Text] [Related]
9. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P
Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572
[TBL] [Abstract][Full Text] [Related]
10. Cortisol response patterns in depressed women and their healthy daughters at risk: Comparison with healthy women and their daughters.
Gonul AS; Cetinkalp S; Tunay S; Polat I; Simsek F; Aksoy B; Kizilates G; Erdogan Y; Coburn KL
J Psychiatr Res; 2017 Feb; 85():66-74. PubMed ID: 27837659
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests.
Menke A; Arloth J; Best J; Namendorf C; Gerlach T; Czamara D; Lucae S; Dunlop BW; Crowe TM; Garlow SJ; Nemeroff CB; Ritchie JC; Craighead WE; Mayberg HS; Rex-Haffner M; Binder EB; Uhr M
Psychoneuroendocrinology; 2016 Jul; 69():161-71. PubMed ID: 27107207
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study.
Kunugi H; Ida I; Owashi T; Kimura M; Inoue Y; Nakagawa S; Yabana T; Urushibara T; Kanai R; Aihara M; Yuuki N; Otsubo T; Oshima A; Kudo K; Inoue T; Kitaichi Y; Shirakawa O; Isogawa K; Nagayama H; Kamijima K; Nanko S; Kanba S; Higuchi T; Mikuni M
Neuropsychopharmacology; 2006 Jan; 31(1):212-20. PubMed ID: 16123748
[TBL] [Abstract][Full Text] [Related]
13. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
Ising M; Horstmann S; Kloiber S; Lucae S; Binder EB; Kern N; Künzel HE; Pfennig A; Uhr M; Holsboer F
Biol Psychiatry; 2007 Jul; 62(1):47-54. PubMed ID: 17123470
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
[TBL] [Abstract][Full Text] [Related]
15. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.
Schmid DA; Wichniak A; Uhr M; Ising M; Brunner H; Held K; Weikel JC; Sonntag A; Steiger A
Neuropsychopharmacology; 2006 Apr; 31(4):832-44. PubMed ID: 16237393
[TBL] [Abstract][Full Text] [Related]
16. The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a randomized trial.
Sarubin N; Nothdurfter C; Schüle C; Lieb M; Uhr M; Born C; Zimmermannc R; Bühner M; Konopka K; Rupprecht R; Baghai TC
J Psychiatr Res; 2014 Jun; 53():76-83. PubMed ID: 24655586
[TBL] [Abstract][Full Text] [Related]
17. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
Binder EB; Künzel HE; Nickel T; Kern N; Pfennig A; Majer M; Uhr M; Ising M; Holsboer F
Psychoneuroendocrinology; 2009 Jan; 34(1):99-109. PubMed ID: 18829172
[TBL] [Abstract][Full Text] [Related]
18. Psychological and endocrine responses to psychosocial stress and dexamethasone/corticotropin-releasing hormone in healthy postmenopausal women and young controls: the impact of age and a two-week estradiol treatment.
Kudielka BM; Schmidt-Reinwald AK; Hellhammer DH; Kirschbaum C
Neuroendocrinology; 1999 Dec; 70(6):422-30. PubMed ID: 10657735
[TBL] [Abstract][Full Text] [Related]
19. Enhanced suppression of adrenocorticotropic hormone and cortisol responses to hypothalamic-pituitary-adrenal function and thyrotropin-releasing hormone tests after stressful life events in patients with major depressive disorder.
Hikichi T; Akiyoshi J; Ichioka S; Tanaka Y; Tsuru J; Goto S; Matsushita H; Hanada H; Isogawa K; Nagayama H
Neuropsychobiology; 2007; 55(1):21-7. PubMed ID: 17556849
[TBL] [Abstract][Full Text] [Related]
20. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression.
Wichniak A; Brunner H; Ising M; Pedrosa Gil F; Holsboer F; Friess E
Psychoneuroendocrinology; 2004 Oct; 29(9):1101-8. PubMed ID: 15219633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
